Evogene Ltd. EVGN
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -14.25M | -15.21M | -20.28M |
| Total Depreciation and Amortization | -- | -- | 1.16M | 1.02M | 2.59M |
| Total Amortization of Deferred Charges | -- | -- | 1.13M | 797.00K | -- |
| Total Other Non-Cash Items | -- | -- | -4.51M | -5.11M | 398.00K |
| Change in Net Operating Assets | -- | -- | -1.14M | -2.27M | -621.00K |
| Cash from Operations | -- | -- | -17.62M | -20.77M | -17.91M |
| Capital Expenditure | -- | -- | -581.00K | -605.00K | -898.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 26.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 7.92M | 12.15M | -3.53M |
| Cash from Investing | -- | -- | 7.34M | 11.54M | -4.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -644.00K | -801.00K | -1.06M |
| Issuance of Common Stock | -- | -- | 5.54M | 5.62M | 8.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -11.00K | 46.00K | 10.58M |
| Cash from Financing | -- | -- | 9.17M | 4.87M | 17.94M |
| Foreign Exchange rate Adjustments | -- | -- | 29.00K | -51.00K | -164.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -1.16M | -4.42M | -4.53M |